Search results

  1. E

    Long COVID is associated with severe cognitive slowing - a multicentre cross-sectional study, 2023, Stallmach et al

    Now published as Long COVID is associated with severe cognitive slowing: a multicentre cross-sectional study in the Lancet eClinicalMedicine.
  2. E

    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19, 2024, Can et al

    Of course there will be differences I'm not able to comprehend, but at a first glance this essentially seems like a chinese version of Paxlovid, a 3CL inhibitor boosted by ritonavir (there's an abundance of other similar antivirals...
  3. E

    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19, 2024, Can et al

    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19 Abstract BACKGROUND Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential efficacy in a...
  4. E

    SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency, 2024, Li et al

    This study should be interesting to anybody interested in viral persistence. I have wondered why the viral persistence researchers have largerly ignored immunocompromised patients for whom there is a lot of data that they can have a persistent infection for weeks or even months, but that there...
  5. E

    SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency, 2024, Li et al

    SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency Editor’s summary Interrogating Infection in Immunosuppression. Individuals who are immunosuppressed remain at increased risk of severe COVID-19, but this heterogenous patient pool should not be considered a...
  6. E

    Preprint Effect of Paxlovid Treatment on Long COVID Onset: An EHR-Based Target Trial Emulation from N3C, 2024, Preiss et al.

    Unfortunately, the data is pointing towards exactly the opposite direction. It seems to reduce nothing in regards to ME/CFS and only things related to a severe acute infection. In this recent presentation by the lead author of the Metformin studies the researcher is very open about the fact...
  7. E

    Low handgrip strength is associated with worse functional outcomes in long COVID, Fernando Almeida-Val et al, 2024

    Haven't read the study but low HGS was one of the markers leading to a worse prognosis in Scheibenbogen's long-term ME/CFS-like LC study: Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: results from a prospective observational cohort, 2023.
  8. E

    Chronically Ignored - Investigative Documentary

    Homepage:https://www.inselfilm.de/portfolio-item/chronically-ignored/ »Chronically Ignored« is an investigative documentary about a dark chapter in the history of medicine. Why has a devastating, multi-systemic disease like ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome) been...
  9. E

    All-Cause and Cause-Specific Mortality Among Individuals With Hypochondriasis, 2023, Mataix-Cols et al.

    The idea here will be that things such as chronic stress lead to more negative health outcomes. It's very reasonable that, that will be true to some degree especially if there are higher suidice rates, as is the case here. Of course there will be significant confounders as well, such as...
  10. E

    CAR-T therapy

    A new artice in Nature discussing the hope of curing autoimmune diseases, includes a discussion on CAR-T therapy and CAAR-T therapy and why one should be careful about being too optimistic: Can autoimmune diseases be cured? Scientists see hope at last.
  11. E

    Protocol REVERSE-Long COVID-19 With Baricitinib Study (REVERSE-LC)

    At 11:25 on this Twitter interview Ely states that he has received 30 million from the NIH to run the Baricitinib trial, so that should confirm it.
  12. E

    Protocol REVERSE-Long COVID-19 With Baricitinib Study (REVERSE-LC)

    Scheibenbogen is also going to conduct a Baricitinib trial (at least those were her original plans https://pbs.twimg.com/media/FbtnFb8WIAEQq4G?format=jpg&name=large). Do you have details on this? The grant amount seems to be for the whole time period (at least that's what the webpage seems to...
  13. E

    Protocol REVERSE-Long COVID-19 With Baricitinib Study (REVERSE-LC)

    REVERSE-Long COVID-19 With Baricitinib Study (REVERSE-LC) The largest study on Long-Covid initiated by Wes Ely is starting in the upcoming months. In this large (n=550) Randomized, placebo-controlled, double-blind, parallel-design superiority design Phase 3 trial for Long-Covid 4 mg of...
  14. E

    Explaining Long COVID: A Pioneer Cross-Sectional Study Supporting the Endocrine Hypothesis, 2024, Ach et al

    Abstract Context In some patients, symptoms may persist after COVID-19, defined as long COVID. Its pathogenesis is still debated and many hypotheses have been raised. Objective Our primary objective was to evaluate the corticotroph and somatotroph functions of patients previously infected with...
  15. E

    Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome, 2023, Stavrakis et al

    Can't read this, but I'd like to know how they measured antiadrenergic autoantibodies since for Celltrend at least it's known there's no difference in the levels of POTS patients and healthy controls. Isn't it also kind of obvious whether you're getting the placebo or the real thing since one...
  16. E

    Excitable dynamics of flares and relapses in autoimmune diseases 2023 Lebel et al

    If I remember the above study correctly the authors claim that most mathematical models are systems of ODEs and you state that some inherent properties of autoimmune diseases are stochastic and should be modelled as such. Unless I’m missing something that would mean there’s some sort of gap in...
  17. E

    News from Germany

    No information on whether this is ill-intentioned or not as far as I can tell.
  18. E

    1/18/2024 US Senate hearing on Long Covid of the HELP (Health, Labor, Education & Pensions) committee

    I agree, which is why I argued that thus far I wouldn't call anything "change" yet. Apart from politics the medical research community, doctors and healthcare sectors are also quite important, there seems to be very little progress there and the progress that exists, may just be temporary and...
  19. E

    Persistent complement dysregulation with signs of thromboinflammation in active Long Covid, 2024, Boyman et al

    Could the so-called "Covid-toes" be a sign of that or would it be more likely that, that would hav something to do with blood pooling or something else?
  20. E

    Excitable dynamics of flares and relapses in autoimmune diseases 2023 Lebel et al

    @Jonathan Edwards do you think it would be fruitful to pick an autoimmune disease that is somewhat better understood and try to model things from there? Is there sufficient understanding at some scale or on a subset of something to have a meaningful model? I don't think the goal could be for...
Back
Top Bottom